Search Results - "Noursalehi, M."

Number of blastocysts and patient age are the best predictors of live birth after IVF when compared to AMH, FSH, or response to COH by Trukhacheva, E, Rana, N, Noursalehi, M, Dmowski, P

Get full text

Number of blastocysts available for transfer during IVF cycle and patient age are the best predictors of pregnancy when compared to AMH, FSH, or response to COH by Trukhacheva, E, Ding, J, Rana, N, Noursalehi, M, Dmowski, P

Get full text

Impact of an educational initiative on applied knowledge and attitudes of physicians who treat sexual dysfunction by Shabsigh, R, Sadovsky, R, Rosen, R C, Carson, C C, Seftel, A D, Noursalehi, M

“…A randomized, blinded, multicenter, controlled study was undertaken to assess the impact of a multiyear continuing medical education (CME) initiative on…”
Get full text

MUSCLE FUNCTION & HOMEOSTASIS / MOLECULAR THERAPEUTIC APPROACHES by Shieh, P., Kuntz, N., Bönnemann, C., Müller-Felber, W., Lawlor, M.W., Servais, L., Smith, B., Noursalehi, M., Prasad, S., Dowling, J.

Get full text

MUSCLE FUNCTION & HOMEOSTASIS / MOLECULAR THERAPEUTIC APPROACHES: P.62 ASPIRO Gene therapy trial in X-linked myotubular myopathy (XLMTM): Update on preliminary safety and efficacy findings up to 72 weeks post-treatment by Shieh, P., Kuntz, N., Bönnemann, C., Müller-Felber, W., Lawlor, M.W., Servais, L., Smith, B., Noursalehi, M., Prasad, S., Dowling, J.

Get full text

CLINICAL TRIAL HIGHLIGHTS by Shieh, P., Kuntz, N., Dowling, J., Müller-Felber, W., Blaschek, A., Bönnemann, C., Foley, R., Saade, D., Seferian, A., Servais, L., Lawlor, M., Noursalehi, M., Prasad, S., Rico, S., Miller, W.

Get full text

CLINICAL TRIAL HIGHLIGHTS: O.1 ASPIRO gene therapy trial in X-linked myotubular myopathy (XLMTM): update on preliminary efficacy and safety findings by Shieh, P., Kuntz, N., Dowling, J., Müller-Felber, W., Blaschek, A., Bönnemann, C., Foley, R., Saade, D., Seferian, A., Servais, L., Lawlor, M., Noursalehi, M., Prasad, S., Rico, S., Miller, W.

Get full text

O.39ASPIRO phase 1/2 gene therapy trial in X-linked motubular myopathy (XLMTM): update on preliminary safety and efficacy findings by Dowling, J., Shieh, P., Kuntz, N., Bonnemann, C., Muller-Felber, W., Lawlor, M., Servais, L., Smith, B., Noursalehi, M., Rico, S., Prasad, S.

Get full text

CONGENITAL MYOPATHIES (CNM): P.138The CHOP INTEND scale (Children's Hospital of Philadelphia infant test of neuromuscular disorders) in X-linked myotubular myopathy: content validity and psychometric performance by Rico, S., Bilder, D., Duong, T., James, E., Noursalehi, M., Bergman, S., Harding, G., Mannix, S., Phillips, D., Abel, C., Prasad, S.

Get full text

NEW THERAPEUTIC APPROACHES AND THEIR READOUT: O.17ASPIRO phase 1/2 gene therapy trial In X-linked myotubular myopathy: preliminary safety and efficacy findings by Kuntz, N., Shieh, P., Smith, B., Bönnemann, C., Dowling, J., Lawlor, M., Müller-Felber, W., Noursalehi, M., Rico, S., Servais, L., Prasad, S.

Get full text

NEW THERAPEUTIC APPROACHES AND THEIR READOUT by Kuntz, N., Shieh, P., Smith, B., Bönnemann, C., Dowling, J., Lawlor, M., Müller-Felber, W., Noursalehi, M., Rico, S., Servais, L., Prasad, S.

Get full text

CONGENITAL MYOPATHIES (CNM) by Rico, S., Bilder, D., Duong, T., James, E., Noursalehi, M., Bergman, S., Harding, G., Mannix, S., Phillips, D., Abel, C., Prasad, S.

Get full text

P.105INCEPTUS pre-phase 1, prospective, non-interventional, natural history run-in study to evaluate subjects aged 4 years and younger with X-linked myotubular myopathy (XLMTM) by Servais, L., Shieh, P., Dowling, J., Kuntz, N., Müller-Felber, W., Smith, B., Bönnemann, C., Muntoni, F., Bilder, D., Duong, T., Graham, R., Jain, M., Lawlor, M., MacBean, V., Noursalehi, M., Pitts, T., Rafferty, G., Rico, S., Prasad, S.

Get full text

CONGENITAL MYOPATHIES (CNM): P.136INCEPTUS pre-phase 1, prospective, non-interventional, natural history run-in study to evaluate subjects aged 3 years and younger with X-linked myotubular myopathy: preliminary findings by Shieh, P., Müller-Felber, W., Smith, B., Bönnemann, C., Dowling, J., Kuntz, N., Muntoni, F., Servais, L., Bilder, D., Duong, T., Graham, R., Jain, M., Lawlor, M., MacBean, V., Noursalehi, M., Pitts, T., Rafferty, G., Rico, S., Prasad, S.

Get full text

CONGENITAL MYOPATHIES (CNM) by Shieh, P., Müller-Felber, W., Smith, B., Bönnemann, C., Dowling, J., Kuntz, N., Muntoni, F., Servais, L., Bilder, D., Duong, T., Graham, R., Jain, M., Lawlor, M., MacBean, V., Noursalehi, M., Pitts, T., Rafferty, G., Rico, S., Prasad, S.

Get full text

Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome by Gadek, James E, DeMichele, Stephen J, Karlstad, Michael D, Pacht, Eric R, Donahoe, Michael, Albertson, Timothy E, Van Hoozen, Chi, Wennberg, Ann K, Nelson, Jeffrey L, Noursalehi, Mojtaba

“…OBJECTIVESRecent studies in animal models of sepsis-induced acute respiratory distress syndrome (ARDS) have shown that a low-carbohydrate, high-fat diet…”
Get full text

51 RADIOLOGIC PROGRESSION PREDICTS OVERALL SURVIVAL IN PATIENTS (PTS) WITH ANDROGEN INDEPENDENT PROSTATE CANCER (AIPC) WHO RECEIVED FIRST LINE DOCETAXEL; AN ANALYSIS FROM THE SPARC TRIAL by Witjes, J.A, Petrylak, D, Sartor, O.A, Noursalehi, M, Sternberg, N, Wirth, M, Billiet, I, Petrone, M.E, McKeam, T.J, George, M

Get full text

Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial by Halabi, S., Sartor, O., Petrylak, D., Sternberg, C. N., Witjes, J. A., Noursalehi, M., McKearn, T. J., George, M. J.

“…Abstract only 5150 Background: It has been shown in chemotherapy naïve patients that PFS is a statistically significant predictor of OS. The main objectives of…”
Get full text

Dexmedetomidine does not alter the sweating threshold, but comparably and linearly decreases the vasoconstriction and shivering thresholds by TALKE, P, TAYEFEH, F, SESSLER, D. I, JEFFREY, R, NOURSALEHI, M, RICHARDSON, C

“…Clonidine decreases the vasoconstriction and shivering thresholds. It thus seems likely that the alpha2 agonist dexmedetomidine will also impair control of…”
Get full text

Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial by Sartor, A. O., Petrylak, D., Sternberg, C., Witjes, F., Halabi, S., Berry, W., Petrone, M., McKearn, T., Noursalehi, M., George, M.

“…Abstract only 5148 Background: First-line chemotherapy trials have reported that pain predicts OS in CRPC. We report relationships between OS and baseline pain…”
Get full text